Omalizumab (Xolair®) increased the time to first exacerbation in patients with moderate-to-severe asthma compared with placebo

被引：0
|
作者：
O'Brien, JA
Fox, H
Thirlwell, J
机构：
[1] City Pk Med Ctr, Cape Town, South Africa
[2] Novartis Res Ctr, Horsham, W Sussex, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2001年 / 107卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
358
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [1] Omalizumab (Xolair®) increases the number of asthma controlled days in moderate-to-severe asthma patients compared to placebo
    Chung, F
    Fox, H
    Thirlwell, J
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S112 - S112
  • [2] Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma
    Omarjee, Bashir
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [3] Omalizumab (Xolair®) increased FEV1 in asthma patients compared to placebo
    Matz, J
    Fox, H
    Thirlwell, J
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S315 - S315
  • [4] Omalizumab (Xolair) May Normalize IgE Production Rate In Patients With Moderate-To-Severe Atopic Asthma
    Lowe, P.
    Tannenbaum, S.
    Gautier, A.
    Massanari, M.
    Panahloo, Z.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S152 - S152
  • [5] The Xolair Pregnancy Registry (EXPECT): Perinatal outcomes among pregnant women with asthma treated with omalizumab (Xolair) compared against those of a cohort of pregnant women with moderate-to-severe asthma
    Namazy, Jennifer A.
    Blais, Lucie
    Andrews, Elizabeth B.
    Scheuerle, Angela E.
    Cabana, Michael D.
    Thorp, John M.
    Veith, Joachim H.
    Umetsu, Dale T.
    Sun, Diana
    Kaufman, Derrick G.
    Covington, Deborah L.
    Mukhopadhyay, Santanu
    Fogel, Robert B.
    Lopez-Leon, Sandra
    Spain, Vic
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB103 - AB103
  • [6] The Xolair Pregnancy Registry (EXPECT): Perinatal Outcomes among Pregnant Women with Asthma Treated with Omalizumab (Xolair) Compared against Those of a Cohort of Pregnant Women with Moderate-to-Severe Asthma
    Namazy, J.
    Blais, L.
    Andrews, E. B.
    Scheuerle, A. E.
    Cabana, M. D.
    Thorp, J. M.
    Veith, J. H.
    Umetsu, D.
    Sun, D.
    Kaufman, D. G.
    Convington, D. L.
    Mukhopadhyay, S.
    Fogel, R.
    Lopez-Leon, S.
    Spain, V
    BIRTH DEFECTS RESEARCH, 2019, 111 (09): : 481 - 481
  • [7] Omalizumab Responder Analysis In Chinese Patients With Moderate-To-Severe Asthma
    Li, J.
    Kang, J.
    Wang, C.
    Yang, J.
    Wang, L.
    Humphries, M.
    Greenberg, S.
    Zhong, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [8] Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
    Long, Aidan
    Rahmaoui, Abdelkader
    Rothman, Kenneth J.
    Guinan, Eva
    Eisner, Mark
    Bradley, Mary S.
    Iribarren, Carlos
    Chen, Hubert
    Carrigan, Gillis
    Rosen, Karin
    Szefler, Stanley J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (03) : 560 - +
  • [9] Clinical Response Predictive Model for Omalizumab in Moderate-to-Severe Asthma Patients
    Qian, Ruiqi
    Yang, Lingyi
    Shen, Xurui
    Chen, Cheng
    Huang, Jianan
    Zhang, Xiuqin
    Fu, Cuiping
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024
  • [10] Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab
    Chen, Hubert
    Eisner, Mark D.
    Haselkorn, Tmirah
    Trzaskoma, Benjamin
    RESPIRATORY MEDICINE, 2013, 107 (01) : 60 - 67
12345